EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1155-1158 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1155 - 1158
Section III - Un futur en développement
DOI https://doi.org/10.1051/medsci/200925121155
Published online 15 December 2009
  1. Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22 : 238–44. [Google Scholar]
  2. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314 : 628–31. [Google Scholar]
  3. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab’ gamma)2 antibody containing thioether-linked Fab’ gamma fragments. J Immunol 1987; 139 : 2367–75. [Google Scholar]
  4. Behar G, Sibéril S, Groulet A, et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008; 21 : 1–10. [Google Scholar]
  5. Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9 : 319–26. [Google Scholar]
  6. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321 : 974–7. [Google Scholar]
  7. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363 : 446–8. [Google Scholar]
  8. Willems A, Schoonooghe S, Eeckhout D, et al. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation. Cancer Immunol Immunother 2005; 54 : 1059–71. [Google Scholar]
  9. Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25 : 1290–7. [Google Scholar]
  10. Baeuerle PA, Reinhardt C, Kufer P. BiTE : a new class of antibodies that recruit T-cells. Drugs of the Future 2008; 33 : 137–47. [Google Scholar]
  11. Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates : enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989; 30 : 1358–66. [Google Scholar]
  12. Goldenberg DM, Chatal J, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007; 2 : 19–31. [Google Scholar]
  13. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008; 49 : 158–63. [Google Scholar]
  14. Robert B, Dorvillius M, Buchegger F, et al. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int J Cancer 1999; 81 : 285–91. [Google Scholar]
  15. Dorvillius M, Garambois V, Pourquier D, et al. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens : ErbB-2 and carcinoembryonic antigen. Tumour Biol 2002; 23 : 337–47. [Google Scholar]
  16. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99 : 1415–25. [Google Scholar]
  17. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280 : 19665–72. [Google Scholar]
  18. Qu Z, Goldenberg DM, Cardillo TM, et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111 : 2211–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.